Zhi-Ming Shao, Peng Ji, Tong Liu, Huawei Yang, Yi Zeng, Xiaoke Hou, Chunping Liu, Xiaoping Li, Nanlin Li, Zhong Ouyang, Xiaobo Wu, Yanxiang Guo, Guohui Han, Shien Cui, Zhijun Zhu, Yu Zhang, Wei Huang, Silong Xiang, Kai Zou, Hang He. "Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.17_suppl.lba660